Publication Topic

Keeton KA, Blanchette A, Benson SM, Covell LT, Madl AK. Analysis and comparison of nicotine pharmacokinetics of modern oral nicotine pouches. Poster Presentation 48 at the 77th Tobacco Science Research Conference, Atlanta, GA, September 2024.

Racz L, Mittal L, Perry CS, Blanchette A, Proctor D. Assessing sustainable applications of electric arc furnace steel slag as construction aggregate: Applications of probabilistic risk assessment and physiologically-based pharmacokinetic modeling. Poster presented at Society of Environmental Toxicology and Chemistry North America 44^th Annual Meeting, Louisville, KY, November 2023.

Perry CS, Blanchette AD, Vivanco SN, Verwiel AH, Proctor DM. 2023. Use of physiologically based pharmacokinetic modeling to support development of an acute (24-hour) health-based inhalation guideline for manganese. Regul Toxicol Pharmacol 145:105518; doi: 10.1016/j.yrtph.2023.105518. PMID: 3786341.

Grover A, Sankaranarayanan S, Mathur V, Suri P, Qiu H, Andrews-Zwilling Y, Mease K, Taylor LK, Cahir-McFarland E, Keswani S, Yednock T. 2023. Pharmacokinetic and target engagement measures of ANX007, an anti-C1q antibody fragment, following intravitreal administration in nonhuman primates. Invest Opthalmol Visual Sci 64(2)3; 10.1167/iovs.64.2.3. PMID: 36729444.

Ramírez-Valle F, Adams M, Beebe L, Chen J, Chuaqui C, Connarn JN, Corin AF, Dingley KH, et al. 2019. A novel MK2 inhibitor for the treatment of ankylosing spondylitis and other inflammatory diseases. Abstract 1536, Annual Meeting of the American College of Rheumatology Conference, Atlanta, GA, November 2019.

Casey WM, Chang X, Allen DG, Ceger PC, Choksi NY, Hsieh JH, et al. 2018. Evaluation and optimization of pharmacokinetic models for in vitro to in vivo extrapolation of estrogenic activity for environmental chemicals. Environ Health Perspect 126(9):97001; doi: 10.1289/EHP1655.

Thompson CM, Kirman CR, Hays SM, Suh M, Harvey SE, Proctor DM, Rager JE, Haws LC, Harris MA. 2018. Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium. J Appl Toxicol 38:351–365. doi: 10.1002/jat.3545.

Harper BH, Wang L, Zhu C, Kar NF, Li B, Moyes CR, … Dingley K, et al. 2017. Investigation of piperazine benzamides as human β3 adrenergic receptor agonists for the treatment of overactive bladder. Bioorg Med Chem Lett 27(4):1094–1098; doi: 10.1016/j.bmcl.2016.12.033. PMID: 28089699.

Zhu C, Wang L, Zhu Y, Guo ZZ, Liu P, Hu Z, … Dingley KH, et al. 2017. Discovery of phenyl acetamides as potent and selective GPR119 agonists. Bioorg Med Chem Lett 27(5):1124–1128; doi: 10.1016/j.bmcl.2017.01.091. PMID: 28185720.

Kirman CR, Suh M, Proctor DM, Hays SM. 2017. Improved physiologically based pharmacokinetic model for oral exposures to chromium in mice, rats, and humans to address temporal variation and sensitive populations. Toxicol Appl Pharmacol 325(15 June):9-17; doi: 10.1016/j.taap.2017.03.023.

Wilson JE, Kurukulasuriya R, Sinz C, Matthew Lombardo, Kate Bender, Dann Parker, … Dingley K, et al. 2016. Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes. Bioorg Med Chem Lett 26(12):2947–2951; doi: 10.1016/j.bmcl.2016.04.018. PMID: 27240550.

Chang X, Kleinstreuer N, Ceger P, Choksi NY, Hseih J, DeVito M, Allen DG, Casey W. Application of reverse dosimetry to compare in vitro and in vivo estrogen receptor activity. Poster presented at Society of Toxicology 54th Annual Meeting, San Diego, CA, March 2015.

Kirman CR, Thompson CM, Proctor DM, Suh M, Haws LC, Harris MA, Hays SM. 2013. Using PBPK modeling to address diurnal variation and age differences in hexavalent chromium toxicokinetics in humans. Presented at Society of Toxicology 52nd Annual Meeting, March 10-14, San Antonio, TX.

Kirman CR, Hays SM, Aylward LL, Suh M, Proctor D. 2012. Physiologically-based pharmacokinetic model for mice, rats and humans orally-exposed to chromium. Presented at Society of Toxicology 51st Annual Meeting, San Francisco, CA, March 2012.

Urban J, Budinsky R, Rowlands J. 2012. An evaluation of single nucleotide polymorphisms in the human heat shock protein 90kDa alpha and beta isoforms. Drug Metab Pharmacokinet 27(2):268-278; doi: 10.2133/dmpk.DMPK-11-SC-114.

Proctor D, Haws L, Thompson C, Harris M. 2011. Use of mode of action and pharmacokinetics to inform the cancer risk assessment of ingested Cr(VI): A case study. Presented at the Society of Toxicology 50th Annual Meeting, March 6-10, 2011, Washington, D.C.

Covington TR, Jakubowski EM, McGuire JM, Byers CE, Evans RA, Hulet SW, et al. A multi-species and -route ion- and isomer-specific physiologically-based pharmacokinetic-pharmacodynamic model for VX. Presentation at the Chemical and Biological Defense Science and Technology Conference, Dallas, TX, November 2009.

Thompson CM, Sonawane B, Barton HA, DeWoskin RS, Schlosser P, Lipscomb JC, Chiu W, Krishnan K. 2008. Approaches for applications of physiologically based pharmacokinetic models in risk assessment. J Toxicol Environ Health B 11(7):519–547; doi: 10.1080/10937400701724337.

Emond C, Raymer J, Garner E, Diliberto J, Staskal D, Birnbaum LS. A physiologically-based pharmacokinetic model for developmental exposure to PBDE-47 in rodents. Society of Toxicology 46th Annual Meeting, Charlotte, NC, March 2007.

Hack CE, Covington TR, Lawrence G, Shipp AM, Gentry R, Yager J, Clewell, HJ, III. 2007. A pharmacokinetic model of the intracellular dosimetry of inhaled nickel. J Toxicol Environ Health A 70(5):445–464; doi: 10.1080/15287390600870726.